ABBV-399
Showing 1 - 25 of 114
NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Telisotuzumab Vedotin
- +4 more
- (no location specified)
Oct 17, 2023
Advanced Solid Tumors Cancer Trial in Worldwide (Osimertinib, Nivolumab, Telisotuzumab vedotin)
Recruiting
- Advanced Solid Tumors Cancer
- Osimertinib
- +3 more
-
Scottsdale, Arizona
- +35 more
Jan 12, 2023
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7 Trial in Houston (ABBV-399)
Completed
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC V7
- ABBV-399
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2021
NSCLC (NSCLC) Trial in West Perth, Yau Ma Tei, Petakh Tikva (Telisotuzumab vedotin)
Available
- Non-Small Cell Lung Cancer (NSCLC)
- Telisotuzumab vedotin
-
West Perth, Western Australia, Australia
- +2 more
Feb 24, 2022
Advanced Solid Tumors Cancer Trial in Sunto-gun, Chuo-ku (ABBV-399)
Completed
- Advanced Solid Tumors Cancer
- ABBV-399
-
Sunto-gun, Shizuoka, Japan
- +1 more
Mar 12, 2019
Non Small Cell Lung Cancer Trial in Worldwide (Telisotuzumab Vedotin)
Not yet recruiting
- Non Small Cell Lung Cancer
- Telisotuzumab Vedotin
-
Clayton, Victoria, Australia
- +54 more
Aug 23, 2022
Specific Protein Overexpression in Adult Non-Small Cell Lung
Not yet recruiting
- Non Small Cell Lung Cancer
- (no location specified)
Sep 29, 2023
Non Small Cell Lung Cancer Trial in Worldwide (Telisotuzumab Vedotin, Docetaxel)
Recruiting
- Non Small Cell Lung Cancer
- Telisotuzumab Vedotin
- Docetaxel
-
Los Angeles, California
- +212 more
Jan 26, 2023
ABBV-951 Subcutaneous Infusion to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Oct 25, 2023
Subcutaneous Infusion of ABBV-951 to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Jun 15, 2023
Advanced Solid Tumors Cancer Trial in Worldwide (ABBV-151, Budigalimab)
Recruiting
- Advanced Solid Tumors Cancer
-
New Haven, Connecticut
- +29 more
Dec 5, 2022
ABBV-154 Trial in Grayslake, Las Vegas (ABBV-154 Dose Formulation A, ABBV-154 Dose Formulation B)
Active, not recruiting
- ABBV-154
- ABBV-154 Dose Formulation A
- ABBV-154 Dose Formulation B
-
Grayslake, Illinois
- +1 more
Dec 19, 2022
Upper Limb Spasticity Trial (ABBV-950, BOTOX, Placebo for ABBV-950)
Not yet recruiting
- Upper Limb Spasticity
- ABBV-950
- +2 more
- (no location specified)
Jul 14, 2023
Unresectable Metastatic Colorectal Cancer Trial (ABBV-400, Bevacizumab, Folinic Acid)
Not yet recruiting
- Unresectable Metastatic Colorectal Cancer
- ABBV-400
- +4 more
- (no location specified)
Oct 25, 2023
DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +3 more
-
Louisville, Kentucky
- +6 more
Nov 14, 2022
Relapsed/Refractory Multiple Myeloma Trial in Japan (ABBV-383)
Recruiting
- Relapsed/Refractory Multiple Myeloma
-
Kashiwa-shi, Chiba, Japan
- +5 more
Jan 25, 2023